000 01445 a2200421 4500
005 20250514232739.0
264 0 _c20050927
008 200509s 0 0 eng d
022 _a0090-8258
024 7 _a10.1016/j.ygyno.2005.04.032
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aO'Malley, David M
245 0 0 _aWeekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
_h[electronic resource]
260 _bGynecologic oncology
_cAug 2005
300 _a242-8 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAntineoplastic Agents
_xadverse effects
650 0 4 _aDrug Administration Schedule
650 0 4 _aEpithelial Cells
_xpathology
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMiddle Aged
650 0 4 _aNeoplasm Recurrence, Local
_xdrug therapy
650 0 4 _aOvarian Neoplasms
_xdrug therapy
650 0 4 _aRetrospective Studies
650 0 4 _aTopotecan
_xadministration & dosage
700 1 _aAzodi, Masoud
700 1 _aMakkenchery, Anita
700 1 _aTangir, Jacob
700 1 _aMcAlpine, Jessica
700 1 _aKelly, Michael
700 1 _aSchwartz, Peter
700 1 _aRutherford, Thomas
773 0 _tGynecologic oncology
_gvol. 98
_gno. 2
_gp. 242-8
856 4 0 _uhttps://doi.org/10.1016/j.ygyno.2005.04.032
_zAvailable from publisher's website
999 _c15649852
_d15649852